Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1995-09-12
1998-11-10
LeGuyader, John L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
435 6, 435 9131, 4351723, 4353201, 435325, 435366, 435371, 435375, 536 231, 536 232, 536 245, A61K 4800, C07H 2104, C12N 1585, C12Q 168
Patent
active
058344403
ABSTRACT:
As an effective therapy for restenosis, this invention provides ribozymes and ribozyme delivery systems useful to inhibit abnormal smooth muscle cell proliferation in vascular tissue. Methods of producing ribozymes and gene therapy utilizing these ribozymes also are provided.
REFERENCES:
patent: 4987071 (1991-01-01), Cech et al.
patent: 5225347 (1993-07-01), Goldberg et al.
patent: 5254678 (1993-10-01), Haseloff et al.
Dev et al., "Ribozymes to Cell Division Cycle (CDC-2) Kinase and Proliferating Cell Nuclear Antigen (PCNA) Prevent Intimal Hyperplasia in Rat Carotid Artery," Circulation 92(No. 8 suppl 1): 34, 1995.
Drenser et al., "Control of Gene Expression in Yeast Using Hairpin Ribozymes," Protein Eng. 8(suppl): 88, 1995.
Jarvis et al., "Inhibition of Vascular Smooth Muscle Cell Proliferation by Hammerhead Ribozymes Targeting c-myb," Journal of Cellular Biochemistry Supplement 19A: 221, 1995.
Mann et al., "Genetic engineering of vein grafts resistant to atherosclerosis," Proc. Natl. Acad. Sci. USA 92: 4502-4506, 1995.
Stinchcomb et al., "Towards the Application of Ribozymes to Human Health," Journal of Cellular Biochemistry Supplement 19A: 202, 1995.
Pines, J., "Protein kinases and cell cycle control," Seminars in Cell Biology 5: 399-408, 1994.
Charollais et al., "Into and out or G1: The control of cell proliferation," Biochimie 76: 887-894, 1994.
Pines, J., "Cyclins, CDKs and cancer," Seminars in Cancer Biology 6: 63-72, 1995.
Grana and Reddy, "Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs)," Oncogene 11: 211-219, 1995.
Jaskulski et al., "Inhibition of Cellular Proliferation by Antisense Oligodeoxynucleotides to PCNA Cyclin," Science 240: 1544-1546, 1988.
Nikol et al., "Molecular biology an post-angioplasty restenosis," Atherosclerosis 123: 17-31, 1996.
Isner et al., "Arterial Gene Therapy for Restenosis," Human Gene Therapy 7: 989-1011, 1996.
Haber, E., "Can a Viral Serine Proteinase Inhibitor Prevent Postangioplasty Restenosis?" Circulation 94: 2694-2695, 1996.
Nakamura et al., "Passivation Reduces Restenosis After Coronary Angioplasty of High Grade Stenotic Lesions: Results of SHIPS (SHIga Pravastatin Study),", Cardiovascular Drugs and Therapy 10(4): 475-483, 1996.
Itoh et al., "Arterial Natriuretic Polypeptide inhibits Hypertrophy of Vascular Smooth Muscle Cells," J. Clin. Invest. 86: 1690-1697, 1990.
Bravo, R., "Synthesis of the Nuclear Protein Cyclin (PCNA) and Its Relationship with DNA Replication," Experimental Cell Research 163: 289-293, 1986.
Pickering et al., "Proliferative Activity in Peripheral and Coronary Atherosclerosis Plaque among Patients Undergoing Percutaneous Revascularization," J. Clin. Invest. 91: 1469-1480, 1993.
Bennett and Schwartz, "Antisense Therapy for Angioplasty Restenosis. Some Critical Considerations," Circulation 92: 1981-1993, 1995.
Mattsson and Clowes, "Current Concepts in Restenosis Following Balloon Angioplasty," Trends in Cardiovasc. Med. 5: 200-204, 1995.
Almendral et al., "Cloning and sequence of the human nuclear protein cyclin: Homology with DNA-binding proteins," Proc. Natl. Acad. Sci. USA 84: 1575-1579, 1987.
Pines, J., "The cell cycle kinases," Seminars in Cancer Biology 5: 305-313, 1994.
Liu et al., "Cationic Liposome-mediated Intravenous Gene Delivery," Journal of Biological Chemistry 270(42):24864-24870, 1995.
Guzman et al., "In vivo suppression of injury-induced vascular smooth muscle cell accumulation using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene," Proc. Natl. Acad. Sci. USA 91: 10732-10736, 1994.
French et al., "Percutaneous Transluminal In Vivo Gene Transfer by Recombinant Adenovirus in Normal Porcine Coronary Arteries, Atherosclerosis Arteries, and Two Models of Coronary Restenosis," Circulation 90: 2402-2413, 1994.
Libby et al., "A Cascade Model for Restenosis: A Special Case of Atheresclerosis Progression," Circulation 86(suppl III): III-47-III-52, 1992.
Lincoff et al., "Local Drug Delivery for the Prevention of Restenosis. Fact, Fancy, and Future," Circulation 90(4): 2070-2084, 1994.
Mann et al., "Genetic engineering of vein grafts resistant to atherosclerosis," Proc. Natl. Acad. Sci. USA 92: 4502-4506, 1995.
Epstein et al., "Do Antisense Approaches to the Problem of Restenosis Make Sense?" Circulation 88(3): 1351-1353, 1993.
Landau et al., "Percutaneous Transluminal Coronary Angioplasty," The New England Journal of Medicine 330(14): 981-983, 1994.
Simons et al., "Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo," Nature 359: 67-70, 1992.
Waksman et al., "Endovascular Low-Dose Irradiation Inhibits Neointima Formation After Coronary Artery Balloon Injury in Swine. A Possible Role for Radiation Therapy in Restenosis Prevention," Circulation 91: 1533-1539, 1995.
Snyder et al., "Ribozyme-Mediated Inhibition of bcr-abl Gene Expression in a Philadelphia Chromosome-Positive Cell Line," Blood 82(2): 600-605, 1993.
Morishita et al., "Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neoimtimal hyperplasia," Proc. Natl. Acad. Sci. USA 90: 8474-8478, 1993.
Jaskulski et al., "Regulation of the Proliferation Cell Nuclear Antigen Cyclin and Thymidine Kinase mRNA Levels by Growth Factors," Journal of Biological Chemistry 263(21): 10175-10179, 1988.
Travali et al., "Structure of the Human Gene for the Proliferating Cell Nuclear Antigen," Journal of Biological Chemistry 264(13): 7466-7472, 1989.
Bravo et al, "Changes in the nuclear distribution of cyclin (PCNA) but not its synthesis depend on DNA replication," EMBO Journal 4(3): 655-661, 1985.
Morris and Mathews, "Regulation of Proliferating Cell Nuclear Antigens during the Cell Cycle," Journal of Biological Chemistry 264(23): 13856-13864, 1989.
von der Leyen et al., "Gene therapy inhibiting neointimal vascular lesion: In vivo transfer of endothelial cells nitric oxide synthase gene," Proc. Natl. Acad. Sci. USA 92: 1137-1141, 1995.
Simari et al., "Regulation of Cellular Proliferation and Intimal Formation following Balloon injury in Atherosclerosis Rabbit Arteries," J. Clin. Invest. 98(1): 225-235, 1996.
Shimayama et al., "Nuclease-resistant chimeric ribozymes containing deoxyribonucleotides and phosphorothioate linkages," Nucleic Acids Research 21(11): 2605-2611, 1993.
Taylor et al., "Chimeric DNA-RNA hammerhead ribozymes have enhanced in vitro catalytic efficiency and increased stability in vivo," Nucleic Acids Research 20(17): 4559-4565, 1992.
Simons et al., "Antisense Proliferating Cell Nuclear Antigen Oligonucleotides Inhibit Intimal Hyperplasia in a Rat Carotid Artery Injury Model," J. Clin. Invest. 93: 2351-2356, 1994.
Guzman et al., "Efficient and Selective Adenovirus-Mediated Gene Transfer Into Vascular Neointima," Circulation 88: 2838-2848, 1993.
Steg et al., "Arterial Gene Transfer to Rabbit Endothelial and Smooth Muscle Cells Using Percutaneous Delivery of an Adenoviral Vector," Circulation 90: 1648-1656, 1994.
Nabel, E., "Gene Therapy for Cardiovascular Disease," Circulation 91(2): 541-548, 1995.
Barr et al. "Efficient catheter-mediated gene transfer in the heart using replication-defective adenovirus," Gene Therapy 1: 51-58, 1994.
Biro et al., "Inhibitory effects of antisense oligodeoxynucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration," Proc. Natl. Acad. Sci. USA 90: 654-658, 1993.
Chang et al., "Cytostatic Gene Therapy for Restenosis Using Adenovirus-Mediated Overexpression of the Cyclin/CDK Inhibitor, p21," Circulation Supplement 92(8): 747, abstract #3593, 1995.
Chatterjee et al., "Dual-Target Inhibition of HIV-1 in Vitro by Means of an Adeno-Associated Virus Antisense Vector," Science 258: 1485-1488, 1992.
Content and Mahieu, "Construction of a Ribozyme Cleaving Human IL-6 mRNA," J. Cell. Biochem. Suppl.(17 part B): abstract #E502, p. 110, 1993.
Cotten and Birnstiel, "Ribozyme mediated destruction of RNA in vivo," The EMBO Journal 8(12): 3861-3
Goldenberg Tsvi
Tritz Richard
Immusol Incorporated
LeGuyader John L.
LandOfFree
Ribozyme therapy for the inhibition of restenosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ribozyme therapy for the inhibition of restenosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ribozyme therapy for the inhibition of restenosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1516783